일본의 전임상 CRO 시장 보고서 : 서비스, 최종 용도, 지역별(2025-2033년)

Japan preclinical CRO market size reached USD 243.2 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 539.9 Million by 2033, exhibiting a growth rate (CAGR) of 8.3% during 2025-2033. The market is witnessing significant momentum due to a heightened emphasis among companies on their core strengths and recent breakthroughs in specialized treatments.

A preclinical contract research organization (CRO) is a company that delivers diverse research and development (R&D) services to the biotechnology, pharmaceutical, and medical device sectors. These services encompass a wide spectrum, including toxicology investigations, pharmacokinetic assessments, formulation development, regulatory assistance, and pharmacodynamic studies. The applications of preclinical CRO services span various domains, encompassing drug discovery, medical device evaluation, biocompatibility assessments, disease modeling, safety pharmacology investigations, and the selection of appropriate dosage forms. These services facilitate the acceleration of product development, bolster compliance with regulatory requirements, tap into specialized expertise, optimize resource allocation, and offer flexible research solutions.

Japan Preclinical CRO Market Trends:

In the context of the Japanese market, there is an increasing emphasis among companies on concentrating their efforts on their core competencies. This trend is driving the demand for preclinical contract research organizations (CROs) as they enable companies to delegate specialized preclinical tasks, allowing them to allocate more resources to their primary areas of focus, such as late-phase clinical trials or marketing endeavors. Moreover, the surging demand for preclinical CRO services in Japan is linked to the rapid expansion of the pharmaceutical sector in emerging economies, driven by the need to address unique healthcare challenges and cater to a growing patient population. Additionally, the market is benefiting from recent advancements in specialized treatments like personalized medicine, biologics, and gene therapies, which necessitate precise and nuanced preclinical testing. Furthermore, the widespread adoption of preclinical CROs is driven by the desire to adopt a risk-balanced approach, especially in light of the high failure rate in drug development. Lastly, the introduction of cutting-edge technologies that play a pivotal role in the successful execution of preclinical studies is expected to bolster the market's growth prospects in Japan over the forecasted period.

Japan Preclinical CRO Market Segmentation:

Service Insights:

• Bioanalysis and DMPK Studies
• Toxicology Testing
• Others

End Use Insights:

• Biopharmaceutical Companies
• Government and Academic Institutes
• Medical Device Companies

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

• How has the Japan preclinical CRO market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan preclinical CRO market?
• What is the breakup of the Japan preclinical CRO market on the basis of service?
• What is the breakup of the Japan preclinical CRO market on the basis of end use?
• What are the various stages in the value chain of the Japan preclinical CRO market?
• What are the key driving factors and challenges in the Japan preclinical CRO?
• What is the structure of the Japan preclinical CRO market and who are the key players?
• What is the degree of competition in the Japan preclinical CRO market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Preclinical CRO Market - Introduction

• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Industry Trends
• 4.4 Competitive Intelligence

5 Japan Preclinical CRO Market Landscape

• 5.1 Historical and Current Market Trends (2019-2024)
• 5.2 Market Forecast (2025-2033)

6 Japan Preclinical CRO Market - Breakup by Service

• 6.1 Bioanalysis and DMPK Studies
  • 6.1.1 Overview
  • 6.1.2 Historical and Current Market Trends (2019-2024)
  • 6.1.3 Market Forecast (2025-2033)
• 6.2 Toxicology Testing
  • 6.2.1 Overview
  • 6.2.2 Historical and Current Market Trends (2019-2024)
  • 6.2.3 Market Forecast (2025-2033)
• 6.3 Others
  • 6.3.1 Historical and Current Market Trends (2019-2024)
  • 6.3.2 Market Forecast (2025-2033)

7 Japan Preclinical CRO Market - Breakup by End Use

• 7.1 Biopharmaceutical Companies
  • 7.1.1 Overview
  • 7.1.2 Historical and Current Market Trends (2019-2024)
  • 7.1.3 Market Forecast (2025-2033)
• 7.2 Government and Academic Institutes
  • 7.2.1 Overview
  • 7.2.2 Historical and Current Market Trends (2019-2024)
  • 7.2.3 Market Forecast (2025-2033)
• 7.3 Medical Device Companies
  • 7.3.1 Overview
  • 7.3.2 Historical and Current Market Trends (2019-2024)
  • 7.3.3 Market Forecast (2025-2033)

8 Japan Preclinical CRO Market - Competitive Landscape

• 8.1 Overview
• 8.2 Market Structure
• 8.3 Market Player Positioning
• 8.4 Top Winning Strategies
• 8.5 Competitive Dashboard
• 8.6 Company Evaluation Quadrant

9 Profiles of Key Players

• 9.1 Company A
  • 9.1.1 Business Overview
  • 9.1.2 Product Portfolio
  • 9.1.3 Business Strategies
  • 9.1.4 SWOT Analysis
  • 9.1.5 Major News and Events
• 9.2 Company B
  • 9.2.1 Business Overview
  • 9.2.2 Product Portfolio
  • 9.2.3 Business Strategies
  • 9.2.4 SWOT Analysis
  • 9.2.5 Major News and Events
• 9.3 Company C
  • 9.3.1 Business Overview
  • 9.3.2 Product Portfolio
  • 9.3.3 Business Strategies
  • 9.3.4 SWOT Analysis
  • 9.3.5 Major News and Events
• 9.4 Company D
  • 9.4.1 Business Overview
  • 9.4.2 Product Portfolio
  • 9.4.3 Business Strategies
  • 9.4.4 SWOT Analysis
  • 9.4.5 Major News and Events
• 9.5 Company E
  • 9.5.1 Business Overview
  • 9.5.2 Product Portfolio
  • 9.5.3 Business Strategies
  • 9.5.4 SWOT Analysis
  • 9.5.5 Major News and Events

10 Japan Preclinical CRO Market - Industry Analysis

• 10.1 Drivers, Restraints, and Opportunities
  • 10.1.1 Overview
  • 10.1.2 Drivers
  • 10.1.3 Restraints
  • 10.1.4 Opportunities
• 10.2 Porters Five Forces Analysis
  • 10.2.1 Overview
  • 10.2.2 Bargaining Power of Buyers
  • 10.2.3 Bargaining Power of Suppliers
  • 10.2.4 Degree of Competition
  • 10.2.5 Threat of New Entrants
  • 10.2.6 Threat of Substitutes
• 10.3 Value Chain Analysis

11 Appendix